A carregar...
Using PARP Inhibitors in the Treatment of Patients with Ovarian Cancer
Use of Poly(ADP-Ribose) Polymerase (PARP) inhibitors has greatly increased over the past five years. With several new Food and Drug Administration (FDA) approvals, three PARP inhibitors have entered into standard of care treatment for epithelial ovarian cancer (including ovarian, fallopian tube, and...
Na minha lista:
| Publicado no: | Curr Treat Options Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8240125/ https://ncbi.nlm.nih.gov/pubmed/30535808 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-018-0572-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|